CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines and related symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 04/24/08 | Series C | 16.3M | Rocket Internet, Kohlberg Ventures, SBA Communications, HSBC Group, Morgan Stanley Investment Management, Lazard Asset Management, Ofer Hi-Tech Holdings, Klein Venture Partners | Unknown |
People
Matthew Collier (Board Member)
Gerard Pereira (VP Business Development)
Antoun Nabhan (CFO)
Paul Winner (Board Member)
Joseph Vallner (President/CEO)
News
Capnia breathes in $3.1M to deliver carbon dioxide for medical treatments
February 25, 2010 2:49 am
Capnia, developer of a system used to deliver carbon dioxide to treat medical conditions, has brought in $3.1 million of… Continue reading ⟩
Capnia, a CO2-through-nose treatment company, raises $16.3M
April 24, 2008 1:46 pm
Capnia, a Palo Alto, Calif., company that delivers carbon dioxide through a patient’s nose to treat things like migraines and… Continue reading ⟩
Life sciences briefing: Monday, Aug. 13, 2007
August 13, 2007 8:16 pm
(UPDATED: See below.) Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories… Continue reading ⟩